The Evolution of the Meningitis Vaccine Project | Zendy

Kathleen Tiffay | Zendy; Luis Jódar | Zendy; Marie-Paule Kiény | Zendy; Muriel Socquet | Zendy; F. Marc LaForce | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Evolution of the Meningitis Vaccine Project

Author(s) -

Kathleen Tiffay,

Luis Jódar,

Marie-Paule Kiény,

Muriel Socquet,

F. Marc LaForce

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ594

Subject(s) - medicine , meningitis , meningococcal meningitis , meningococcal vaccine , virology , license , vaccination , bacterial meningitis , family medicine , pediatrics , immunization , neisseria meningitidis , immunology , antibody , political science , biology , bacteria , law , genetics

In 2001, the Meningitis Vaccine Project (MVP) was tasked to develop, test, license, and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan Africa. African public health officials emphasized that a vaccine price of less than US$0.50 per dose was necessary to ensure introduction and sustained use of this new vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research